# Infliximab Biosimilar for Intravenous Drip Infusion 100 mg "Pfizer" Drug Use Investigation (Rheumatoid Arthritis)

> **NCT03885037** · — · COMPLETED · sponsor: **Pfizer** · enrollment: 77 (actual)

## Conditions studied

- Rheumatoid Arthritis

## Interventions

- **DRUG:** Infliximab [infliximab biosimilar 3]

## Key facts

- **NCT ID:** NCT03885037
- **Lead sponsor:** Pfizer
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2019-03-20
- **Primary completion:** 2024-11-29
- **Final completion:** 2024-11-29
- **Target enrollment:** 77 (ACTUAL)
- **Last updated:** 2026-01-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03885037

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03885037, "Infliximab Biosimilar for Intravenous Drip Infusion 100 mg "Pfizer" Drug Use Investigation (Rheumatoid Arthritis)". Retrieved via AI Analytics 2026-07-26 from https://api.ai-analytics.org/clinical/NCT03885037. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*